Skip to main content

Overcoming the challenges, shaping the future

The development of medicines for rare diseases, particularly for children, faces unique challenges, including limited clinical data and the need to consider ethical and practical issues. Despite these obstacles, we are committed to investing in the provision of paediatric medicines. Without specially developed paediatric medicines, young patients are at increased risk of inadequate treatment and potential complications.

Our commitment to rare diseases

Apocare Pharma GmbH is dedicated to the research and development of treatments for rare diseases. The aim is to improve the lives of patients affected by little-known and often neglected diseases.

A rare disease affects less than 1 in 2,000 people. Although each disease is rare in itself, over 300 million people worldwide are affected by one of the many known rare diseases.

The diagnosis of rare diseases is often difficult and time-consuming. Many patients go through an odyssey lasting years before they receive an accurate diagnosis. Furthermore, treatment options are often limited and many diseases remain incurable.

People with rare diseases need advocates. Our focus is to provide the best possible treatment based on scientific evidence to improve medical care and the lives of patients and their families living with a rare disease.


Our team works in close cooperation with medical experts, patient organisations and global partners to make innovative therapies available in Germany. We focus on the development of medicines that are tailored to the specific needs and challenges of rare diseases.

Safety and child-friendly formulations: Our priority

The safety of paediatric medicines is a key concern for us. Apocare Pharma GmbH is committed to careful safety testing and strict quality controls in order to minimise side effects and ensure the protection of our youngest patients. Furthermore, we endeavour to offer medicines in child-friendly dosage forms in order to facilitate the intake of medicines and improve adherence to treatment.